Survival Analysis
Objective: Measurement of survival duration in treated versus untreated R6/2 transgenic mice to assess dose-dependent effects of sodium butyrate on lifespan and neuropathological outcomes
This is a Survival Analysis protocol using mouse as the model organism. The procedure involves 2 procedural steps, 1 materials. Extracted from a 2003 paper published in Journal of Neuroscience.
Model and subjects
mouse • R6/2 transgenic • unknown • Not specified • Not specified
Study window
Estimated timing pending
Core workflow
Animal treatment initiation • Survival monitoring
Primary readouts
- Survival duration (lifespan extension)
- Body weight changes
- Motor performance
- Neuropathological sequelae
Key equipment and reagents
Verified items
0
Direct vendor links
0
Use this page as an execution guide, then fall back to the source paper whenever you need exact exclusions, dosing details, or assay-specific caveats.
Confirm first
- Verify the animal model, intervention setup, and collection timepoints against the source paper.
- Check that every direct vendor link matches the exact specification your lab plans to run.
Use the page like this
- Work through the protocol steps in order and use the inline vendor chips only when you need to source or verify an item.
- Jump to Experimental Context for readouts, data shape, and analysis flow before planning downstream analysis.
Protocol Steps
Start here. The step list is optimized for running the experiment, with direct vendor links available inline when you need to source a cited item.
Animal treatment initiation
R6/2 transgenic mice were treated with sodium butyrate at varying doses to assess dose-dependent effects on survival
Note: Treatment was dose-dependent; specific dosing regimen not detailed in provided text
View evidence from paper
“Pharmacological treatment using the histone deacetylase inhibitor sodium butyrate to modulate transcription significantly extended survival in a dose-dependent manner”
Survival monitoring
Survival duration was monitored and recorded for treated versus untreated R6/2 transgenic mice throughout the study period
Note: Comparison made between treated and untreated control groups
View evidence from paper
“significantly extended survival in a dose-dependent manner, improved body weight and motor performance, and delayed the neuropathological sequelae in the R6/2 transgenic mouse model of HD”